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eripheral Arterial Disease in Patients With Diabetes
teven P. Marso, MD, FACC,* William R. Hiatt, MD†
ansas City, Missouri; and Denver, Colorado
Peripheral arterial disease (PAD) is a chronic, lifestyle-limiting disease and is an independent
predictor of cardiovascular and cerebrovascular ischemic events. Despite the recognition that
PAD is associated with a marked increase in the risk of ischemic events, this particular
manifestation of systemic atherosclerosis is largely underdiagnosed and undertreated. The risk
of PAD is markedly increased among individuals with diabetes, and ischemic event rates are
higher in diabetic individuals with PAD than in comparable non-diabetic populations.
Consequently, early diagnosis and treatment of PAD in patients with diabetes is critically
important in order to reduce the risk of cardiovascular events, minimize the risk of long-term
disability, and improve quality of life. A diagnosis of PAD in patients with diabetes mandates
a multi-faceted treatment approach, involving aggressive risk-factor modification, antiplatelet
therapy, and revascularization procedures. The American Diabetes Association recently
issued a consensus statement on the epidemiology, pathophysiology, diagnosis, and manage-
ment of PAD in patients with diabetes. This article will review the clinical implications of the
consensus statement and highlight the treatment options available in order to help prevent
future ischemic events in diabetic individuals with PAD. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.065921–9) © 2006 by the American College of Cardiology Foundation
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ptherosclerosis is a progressive process affecting multiple
ascular beds; its clinical consequences, which include cor-
nary artery disease (CAD), cerebrovascular disease, and
eripheral arterial disease (PAD), are potentially life-
hreatening (1). Atherosclerotic disease in one vascular bed
ndicates possible disease in others (2).
The risk of atherosclerotic disease is markedly increased
mong individuals with diabetes. The increased risk is inde-
endent of, and additive to, other cardiovascular risk factors.
therosclerosis causes most of the death and disability in
atients with diabetes, particularly in the type 2 diabetic patient
opulation (3). The Verona Diabetes Study showed that
ardiovascular disease is responsible for 44% of all-cause
atalities in the diabetic patient population (4). The duration of
iabetes increases the risk of death from cardiovascular disease,
ndependent of co-existing risk factors (5). Insulin resistance is
key factor in the pathogenesis of diabetes. Insulin resistance
nd its attendant metabolic abnormalities may cause much of
he increased cardiovascular risk of diabetes (6).
Epidemiological studies have confirmed an association be-
ween diabetes and an increased prevalence of PAD (7,8).
eripheral arterial disease is usually characterized by occlusive
rterial disease of the lower extremities. Although many
atients are asymptomatic, or have atypical exertional symp-
oms, approximately one-third experience intermittent claudi-
ation, described as aching, cramping, or numbness in the
ffected limb, occurring with exercise and relieved at rest (9).
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Manuscript received April 15, 2005; revised manuscript received August 18, 2005,
ccepted September 8, 2005.eripheral arterial disease in patients with diabetes adversely
ffects quality of life (10) and is associated with substantial
unctional impairment (11). The reduced walking speed and
istance associated with intermittent claudication may result in
rogressive loss of function and long-term disability (12,13).
ith more severe disease, critical limb ischemia (CLI) may
evelop, resulting in ischemic ulceration of the foot and risk of
imb loss (14,15). Importantly, PAD is associated with a
ubstantial increase in the risk of fatal and non-fatal cardiovas-
ular and cerebrovascular events, including myocardial infarc-
ion (MI) and stroke (16,17). Patients with diabetes and PAD
re at higher risk of lower extremity amputation than those
ithout diabetes (18). Furthermore, cardiovascular and cere-
rovascular event rates are higher in diabetic individuals with
AD than in comparable non-diabetic populations (12).
Although much is known about PAD in the general
opulation, the management of PAD in those with diabetes is
ess clear. Recently, the American Diabetes Association
ADA) issued a consensus statement that provides guidelines
or the diagnosis and management of PAD in patients with
iabetes (12). The purpose of this article is to review the
onsensus statement and to discuss the treatment options
vailable to help prevent future ischemic events in diabetic
ndividuals with PAD. Patients with diabetes are clearly a
igh-risk group of individuals who are at risk of developing
xtensive vascular disease requiring a multi-discipline ap-
roach. Cardiovascular healthcare providers have a unique
pportunity to reduce the disease burden in this population.
PIDEMIOLOGY
eripheral arterial disease affects approximately 12 million
eople in the U.S.; approximately 20% to 30% of these patients
ave diabetes. However, accurate assessment of the preva-
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PAD in Patients With Diabetes March 7, 2006:921–9ence of PAD in the diabetic population is confounded by
arious factors: the condition is often asymptomatic; periph-
ral neuropathy may alter pain perception; and two of the
ommon clinical findings, the absence of peripheral pulses
nd the presence of claudication, are inadequate diagnostic
ndicators (12). In studies using the ankle-brachial index
ABI), which is the preferred screening technique, the preva-
ence of PAD (defined as an ABI 0.90) in diabetic individ-
als ranges from 20% to 30% (19–21).
The duration and severity of diabetes correlates with the
ncidence and extent of PAD (18). In a prospective cohort
tudy, Al-Delaimy et al. (22) found a strong positive
ssociation between the duration of diabetes and the risk of
eveloping PAD. The association was particularly strong
mong men with hypertension or who were current smokers.
dler et al. (23) estimated the prevalence of PAD up to 18
ears after the diagnosis of diabetes in 4,987 subjects
United Kingdom Prospective Diabetes Study [UKPDS]).
he data showed a higher prevalence of PAD in those with
onger duration of diabetes. The degree of diabetic control
s an independent risk factor for PAD; with every 1%
ncrease in glycosylated hemoglobin, the risk of PAD has
een shown to increase by 28% (24). The risk of PAD is
ssociated with advancing age and the presence of peripheral
europathy (12). In addition, the risk is higher in those of
frican-American or Hispanic descent compared with non-
ispanic white individuals, even after adjustment for other
nown risk factors and the increased prevalence of diabetes in
hese populations. In a community-based study, African-
merican subjects had a lower mean ABI and a greater
revalence of PAD than their non-Hispanic white counter-
arts (25).
Patients with diabetes more commonly develop symp-
omatic PAD. In the Framingham study, the presence of
iabetes increased the risk of intermittent claudication by
.5-fold in men and 8.6-fold in women (26). Furthermore,
atients with diabetes and PAD are more likely to present
Abbreviations and Acronyms
ABCD  Appropriate Blood Pressure Control in
Diabetes trial
ABI  ankle-brachial index
ADA  American Diabetes Association
CAD  coronary artery disease
CARDS  Collaborative AtoRvastatin Diabetes Study
CLI  critical limb ischemia
CRP  C-reactive protein
CTA  computed tomographic angiography
FDA  Food and Drug Administration
LDL  low-density lipoprotein
MI  myocardial infarction
MRA  magnetic resonance angiography
NO  nitric oxide
PAD  peripheral arterial disease
UKPDS  United Kingdom Prospective Diabetes Studyith an ischemic ulcer or gangrene than patients without biabetes, increasing the risk of lower-extremity amputation
18). Faglia et al. (27) observed a positive trend between
AD severity and amputation rate in patients with diabetes.
eople with diabetes are 15 times more likely to have an
mputation than those without (28), and an annual ampu-
ation incidence rate of 0.6% has been reported in these
atients (29,30).
ATHOPHYSIOLOGY
he pathophysiology of PAD in the diabetic population is
imilar to that in the non-diabetic population. However, the
istribution of peripheral atherosclerosis in patients with
AD and diabetes is often more distal than in patients without
iabetes, and commonly involves the tibial vessels (31).
The abnormal metabolic state that accompanies diabetes
irectly contributes to the development of atherosclerosis;
roatherogenic changes include increases in vascular inflam-
ation and alterations in multiple cell types (3).
Inflammation is an established risk factor for the devel-
pment of atherosclerosis. Elevated levels of C-reactive
rotein (CRP) are strongly associated with the development
f PAD. Furthermore, CRP levels are abnormally elevated
n patients with impaired glucose tolerance (32). In addition
o being a marker of atherosclerosis, elevated levels of CRP
ay also be a risk factor for PAD. C-reactive protein has
rocoagulant effects related to its ability to enhance expres-
ion of tissue factor (33). C-reactive protein also inhibits
ndothelial cell nitric oxide (NO) synthase, resulting in
bnormal regulation of vascular tone, and increases produc-
ion of plasminogen activator inhibitor-1, which inhibits the
ormation of fibrinolytic plasmin from plasminogen (12,34).
Most patients with diabetes and PAD demonstrate gen-
ralized endothelial cell dysfunction. In healthy vessels,
ndothelial cells synthesize NO, a potent vasodilator that
nhibits platelet activation and vascular smooth muscle cell
igration. Diabetes impairs NO-mediated vasodilatation
35). A number of mechanisms contribute to the decreased
ioavailability of endothelium-derived NO in diabetes,
ncluding hyperglycemia, excess free fatty acids, and insulin
esistance (36,37). The effects of endothelial cell dysfunc-
ion increase arterial susceptibility to atherosclerosis.
In addition to reducing NO concentrations, diabe-
es increases the production of vasoconstrictors, such as
ndothelin-1, which increase vascular tone and vascular
mooth muscle cell growth and migration. Diabetes also
timulates other atherogenic pathways in vascular smooth
uscle cells. For example, hyperglycemia activates protein
inase C and nuclear factor kappa-B, increasing the pro-
uction of reactive oxygen species that promote the forma-
ion of atherosclerotic lesions (38). Vascular smooth muscle
ells cultured from patients with diabetes demonstrate
nhanced migration, an important step in the progression to
dvanced plaque formation (39). These cells strengthen the
theroma, making it less likely to rupture and cause throm-
osis. However, Fukumoto et al. (40) demonstrated that
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March 7, 2006:921–9 PAD in Patients With Diabetesdvanced plaques in diabetic individuals have fewer smooth
uscle cells than healthy controls; it is believed that
yperglycemia-induced lipid modifications regulate the apo-
tosis of vascular smooth muscle cells in advanced athero-
clerotic lesions, promoting plaque instability and precipi-
ation of clinical events (41).
Platelet aggregation is enhanced in diabetes. Elevated
lucose levels activate protein kinase C, decrease production
f platelet-derived NO, and increase oxidative stress. In
iabetes, platelets also have increased expression of glyco-
rotein Ib and IIb/IIIa receptors, enhancing their throm-
otic potential (34). In addition to potentiating platelet
ggregation, diabetes augments blood coagulability by in-
reasing the expression of tissue factor and decreasing levels
f anticoagulants, such as antithrombin III. Consequently,
t is more likely that atherosclerotic plaque rupture will
esult in thrombus formation (42).
Thus, alterations in metabolism in diabetes adversely
ffect multiple cell types within the vascular wall. The
ncreased tendency towards coagulation, coupled with im-
aired fibrinolysis, contributes to the enhanced thrombotic
otential characteristic of diabetes.
IAGNOSIS
he main reasons to diagnose PAD in diabetic individuals
re to initiate therapies that decrease the risk of athero-
igure 1. Typical protocol for the diagnosis of peripheral arterial diseas
001;344:1608–21. Copyright © 2001 Massachusetts Medical Society. All
VR  pulse-volume recording; UDS  ultrasonic duplex scanning.hrombotic events, improve quality of life, and decrease aisability. A diagnosis of PAD indicates the presence of
ystemic atherosclerosis that confers additional cardiovascu-
ar risk to the patient with diabetes, and gives further
mpetus to aggressively manage vascular risk factors in this
igh-risk group. A typical protocol for the diagnosis of
AD is shown in Figure 1.
A thorough medical history and physical examination are
f primary importance in evaluating a diabetic individual for
he presence of PAD. Information about the onset and
uration of symptoms, pain characteristics, and any allevi-
ting factors is helpful. The clinical stage of symptomatic
AD can be classified using the Fontaine staging system
17). Fontaine stage I represents those who have PAD but
re asymptomatic; stages IIa and IIb include patients with
ild and moderate-to-severe intermittent claudication, re-
pectively; those with ischemic rest pain are classified in
ontaine stage III; and patients with distal ulceration and
angrene represent Fontaine stage IV. A typical history of
laudication has a low sensitivity, but a high specificity for
AD (43). Physical examination should include blood-
ressure measurement, palpation of peripheral pulses, and
uscultation of pulses and bruits. Palpation of peripheral
ulses should include an assessment of the femoral, popli-
eal, and pedal vessels (12); pulses should be graded as
bsent, diminished, or normal. Dorsalis pedis pulse abnor-
alities are less sensitive for PAD, since up to 30% of these
atients with diabetes. Reprinted with permission from N Engl J Med
reserved. ABI ankle-brachial index; PAD peripheral arterial disease;e in pbnormalities may be due to a congenital absence of the
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PAD in Patients With Diabetes March 7, 2006:921–9orsalis pedis artery (44). The absence of both the dorsalis
edis pulse and the posterior tibial pulse strongly suggests
he presence of PAD, but further diagnostic testing is
equired to confirm the diagnosis.
BI screening. Although physical examination provides
mportant information, additional non-invasive testing is
ecessary to ensure the diagnosis. The ABI is a reproducible
nd reasonably accurate measurement for the detection of
AD. The ABI is defined as the ratio of the ankle systolic
lood pressure divided by the brachial systolic blood pres-
ure, and is normally between 1.00 and 1.40 (45). In PAD,
he ankle systolic blood pressure is less than the brachial
ystolic blood pressure, and the ABI is reduced to 1.00;
AD is defined as an ABI 0.90. Lower ABI values
ndicate more severe PAD and a higher risk of cardiovas-
ular events. In the primary care setting, Mohler et al. (46)
ssessed perceptions of the ABI among 886 clinicians; most
elieved the ABI was useful in the diagnosis of both
ymptomatic (96%) and asymptomatic (89%) PAD (46).
The ADA consensus statement recommends that a
creening ABI be performed in all diabetic individuals 50
ears of age. If normal (0.91 to 1.40), the test should be
epeated every five years. A screening ABI should be
erformed in any patient with symptoms of PAD (12).
nkle-brachial index determinations may be of limited
alue in some patients with diabetes, because calcification of
he tibial arteries may render them non-compressible, re-
ulting in unusually high ABI values (1.40) (47). Under
hese conditions, the ABI cannot distinguish patients who
ave arterial occlusion from those who do not, making the
BI unreliable (16,44). However, an elevated ABI is still
redictive of an increased risk of cardiovascular events, and
ther non-invasive vascular tests should be considered to
ake the diagnosis of PAD (48).
The ABI screening recommendations from the ADA
onsensus statement should be incorporated into clinical
ractice for the following reasons. First, an abnormal ABI is
trongly associated with heightened risk for coronary heart
isease mortality and morbidity. If not performed previ-
usly, screening for concomitant CAD should be considered
n the basis of other clinical indicators of cardiac ischemia
e.g., angina). Second, if PAD is confirmed, an aggressive
econdary prevention medical strategy is warranted. The
ational Cholesterol Education Program/Adult Treatment
anel III guidelines classify diabetes as a coronary heart
isease equivalent and recommend a targeted low-density
ipoprotein (LDL) cholesterol level of 100 mg/dl (49). A
ecent update to these guidelines suggests a target LDL
evel of 70 mg/dl for very high-risk patients (50). This
ecommendation was based on emerging data from the
eart Protection Study (51) and Pravastatin or Atorvastatin
valuation and Infection Therapy (52) which suggest a
ower LDL target in patients with established coronary
ascular disease and a major additional risk factor, such as
iabetes. On the basis of this recommendation, it is reason-
ble to suggest that diabetic individuals with documented SAD, independent of symptoms, be treated to an LDL
arget of 70 mg/dl, but specific clinical trials would need to
e performed to fully substantiate this recommendation.
hird, PAD is underdiagnosed in the primary care setting,
nd this is an important barrier for the optimal secondary
revention of ischemic cardiovascular disease (20). Lastly,
any individuals have rather atypical claudication symp-
oms. A large-scale PAD screening study demonstrated that
nly one-third of patients with documented PAD had
lassical claudication symptoms (43). The remaining pa-
ients either had atypical symptoms or were asymptomatic.
hese data suggest that classical claudication symptoms are
ot a reliable indicator for PAD and are inadequate in
etermining a person’s health status due to PAD.
In the patient with a confirmed PAD diagnosis in whom
urther investigation is required (usually in the context of
lanning a revascularization procedure), the next step would
e a vascular laboratory evaluation for segmental pressure
nd pulse volume recordings. Both hemodynamic tests aid
n the localization of arterial occlusive lesions (12,44). Other
on-invasive imaging techniques, such as ultrasonic duplex
canning or magnetic resonance angiography (MRA), can
e used when more precise measurements of the morpho-
ogical features of occlusions are required (i.e., when con-
idering various revascularization options). Ultrasonic du-
lex scanning can directly visualize vessels, providing
nformation on artery wall thickness, degree of flow turbu-
ence, and changes in blood flow velocity (53). Comprehen-
ive imaging of the peripheral vasculature has traditionally
een possible only with invasive conventional angiography.
owever, with the introduction of MRA and computed
omographic angiography (CTA), non-invasive imaging is
ow a reality (54). Contrast-enhanced MRA produces
mages that are comparable with conventional angiography
55). Recently, the development of CTA has dramatically
mproved image quality and expanded the applications for
on-invasive angiography; consequently, The CTA is re-
lacing conventional angiography in many PAD imaging
tudies (56).
ANAGEMENT
nce diabetic individuals with PAD have been identified,
he aim of medical management is to aggressively modify
ardiovascular risk factors and to prescribe antiplatelet
herapy. It is also important to relieve the symptoms of
ntermittent claudication in order to improve functional
tatus and quality of life.
isk factor modification. Atherosclerotic risk factors for
AD include cigarette smoking, diabetes, dyslipidemia, and
ypertension. Treatment goals are summarized in Table 1.
IGARETTE SMOKING. Cigarette smoking is the most im-
ortant risk factor for the development and progression of
AD. The amount and duration of tobacco use correlate
irectly with the development and progression of PAD (57).
moking cessation increases long-term survival in patients
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March 7, 2006:921–9 PAD in Patients With Diabetesith PAD. In one study, the 10-year survival rate was 82%
n former smokers compared with 46% in continuing
mokers (58).
An effective method of smoking cessation is nicotine
eplacement therapy in combination with the oral antide-
ressant bupropion (59). Jorenby et al. (60) conducted a
ouble-blind, placebo-controlled comparison of sustained-
elease bupropion (244 subjects), a nicotine patch (244
ubjects), bupropion and a nicotine patch (245 subjects),
nd placebo (160 subjects) for smoking cessation. The
bstinence rates at 12 months were 15.6% in the placebo
roup, compared with 16.4% in the nicotine-patch group,
0.3% in the bupropion group (p  0.001), and 35.5% in
he group given bupropion and the nicotine patch (p 
.001). Although abstinence rates were higher with combi-
ation therapy than with bupropion alone, the difference
as not statistically significant. In a recent trial, a combi-
ation of physician advice, nicotine replacement therapy,
nd counseling has been shown to improve long-term
ortality (61).
IABETES. Data to support aggressive glycemic control to
educe the cardiovascular risk associated with PAD are
acking. In the UKPDS, there was evidence that intensive
lycemic control with a sulphonylurea or insulin produced a
on-significant 16% risk reduction for MI and sudden death
ompared with conventional diabetic control with diet (62).
owever, there were no significant differences in diabetes-
elated mortality or all-cause mortality between the inten-
ive and conventional groups. Most of the risk reduction in
he “any diabetes-related” aggregate end point was due to a
5% reduction in microvascular end points (retinopathy,
itreous hemorrhage, or renal failure) rather than macrovas-
ular end points (MI, sudden death, stroke, amputation, or
eath due to PAD). Current guidelines from the ADA
ecommend a target glycosylated hemoglobin level of
7.0% in diabetic individuals in order to prevent microvas-
ular complications (63). It should be noted that the current
ecommendations for glucose control from the ADA con-
ensus statement are not based on clinical trial evidence in
atients with diabetes and PAD. Further study is warranted
n this population, in particular with agents that improve
able 1. Risk Factors and Treatment Goals for Patients With
iabetes and PAD
Risk Factor
Relative Risk Increase
for PAD Treatment Goal
moking 2.5 Cessation
iabetes 4.0 Glycosylated hemoglobin
7%
yslipidemia 1.1 (per 10 mg/dl increase) Low-density lipoprotein
100 mg/dl*
ypertension 1.5 Blood pressure
130/80 mmHg
Consider 70 mg/dl.
PAD  peripheral arterial disease.nsulin sensitivity. fYSLIPIDEMIA. Several large trials with 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitors have dem-
nstrated significant reductions in cardiovascular event rates
n patients with PAD and co-existing CAD (52,64). Lipid-
owering therapy also decreases cardiovascular events in
iabetes. Indeed, patients with diabetes may experience
reater risk reduction by lipid lowering than non-diabetic
ndividuals. In the Scandinavian Simvastatin Survival Study,
imvastatin reduced the risk of total mortality by 43% in
atients with diabetes compared with 29% in those without
he disease (65). Although there are no direct data on
reating dyslipidemia in patients with both diabetes and
AD, published guidelines recommend a target LDL cho-
esterol level of70 mg/dl in this very high-risk group (50).
he ADA consensus statement recommends a target LDL
holesterol level of 100 mg/dl (12). As previously stated,
e acknowledge the discrepancy between the published guide-
ines and the ADA consensus statement, but in the absence of
linical trial data, we would recommend an LDL cholesterol
arget of 70 mg/dl in patients with diabetes and PAD.
Recently, the Collaborative AtoRvastatin Diabetes Study
CARDS) (66) evaluated the efficacy of atorvastatin for the
rimary prevention of cardiovascular events in 2,838 pa-
ients with diabetes and at least one other risk factor for
AD, but without elevated LDL cholesterol levels. The
isk of reaching the primary end point of a first acute major
ardiovascular event was reduced by 37% with atorvastatin
elative to placebo. The CARDS study validated an aggres-
ive approach to lipid management for the primary prevention
f cardiovascular events in patients with diabetes at risk for
AD, irrespective of pre-treatment LDL cholesterol levels.
YPERTENSION. Hypertension increases the high risk of
ardiovascular disease associated with diabetes. However,
he role of intensive blood pressure control in patients with
iabetes and PAD has not been established. In a recent
tudy, blood-pressure lowering in normotensive patients
ith diabetes and PAD was particularly effective in prevent-
ng cardiovascular events (67). The UKPDS showed that
lthough diabetes end points were significantly reduced by
ight blood-pressure control, there was no effect on the risk
f amputation due to PAD (68). Nevertheless, a marked
eduction in vascular events with aggressive hypertension
anagement has been demonstrated in diabetic individuals
69). The ADA consensus supports aggressive blood-
ressure control (130/80 mm Hg) in patients with diabe-
es and PAD to reduce cardiovascular risk (12). Studies,
uch as the Hypertension Optimal Treatment trial and the
ppropriate Blood Pressure Control in Diabetes (ABCD)
rial, have suggested that a lower target blood pressure may
e beneficial (69,70). The ABCD trial demonstrated im-
roved outcomes (particularly non-fatal MI) for patients
ith PAD and diabetes who achieved a blood pressure of
125/75 mm Hg compared with 135/85 mm Hg (70).
ntiplatelet therapy. In addition to the established riskactors, the risk of cardiovascular morbidity and mortality in
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PAD in Patients With Diabetes March 7, 2006:921–9AD patients with diabetes also relates to platelet activity
nd inflammation. Platelet activity can be modified by the
se of antiplatelet agents. The treatment goal is to prevent
hrombus formation and the resultant vascular events.
A meta-analysis of 145 prospective controlled trials of
ntiplatelet therapy (mainly aspirin) has been reported by
he Antiplatelet Trialists’ Collaboration (71). This analysis
ombined data from 100,000 patients, including approx-
mately 70,000 high-risk patients with evidence of cardio-
ascular disease, including PAD. There was a 27% reduc-
ion in the odds ratio in the composite primary endpoint of
I, stroke, and vascular death in patients taking antiplatelet
herapy compared with control subjects. However, when a
ubset of 3,000 patients with claudication was analyzed,
reatment was beneficial for the reduction of cardiovascular
vents, but not statistically significant. The equivocal nature
f these results led the Food and Drug Administration
FDA) to conclude there was insufficient evidence to ap-
rove the use of aspirin for the secondary prevention of
therosclerotic events in patients with PAD (72); nonethe-
ess, its use in these patients has received a guideline
ecommendation (73). Furthermore, aspirin has been shown
o significantly improve vascular graft patency in 3,000
atients with PAD treated with bypass surgery or peripheral
ngioplasty (74). Aspirin at dosages of 80 to 325 mg/day is
ecommended for all diabetic individuals 21 years of age
75), but this recommendation is also not fully supported by
linical trial evidence. Thus, aspirin has an established role
n secondary prevention in patients at high risk, with clinical
vidence of either CAD or stroke. However, the role of
spirin in other populations, such as in patients with either
AD or diabetes, without clinical evidence of CAD or
troke, has not been established.
Clopidogrel, an adenosine diphosphate receptor antago-
ist, has potent antiplatelet activity. The Clopidogrel versus
spirin in Patients at Risk of Ischemic Events (CAPRIE)
tudy (76) was the first to evaluate aspirin versus clopidogrel
n patients with recent stroke, recent MI, or established
AD. The study compared clopidogrel at 75 mg/day with
spirin at 325 mg/day in 19,000 patients (approximately
0% with diabetes). Patients treated with clopidogrel had an
nnual 5.32% risk of stroke, MI, or vascular death compared
ith a 5.83% risk in those treated with aspirin. This
epresented a significant 8.7% relative-risk reduction in
avor of clopidogrel (p  0.043). In a subset analysis of
,452 patients with PAD, clopidogrel recipients had a
3.8% relative-risk reduction compared with aspirin recip-
ents (p  0.0028) (Fig. 2), with an annual event rate of
.71% compared with 4.86%. Furthermore, in the PAD
ubgroup, approximately one-third of the patients had
iabetes; in these patients, clopidogrel was also superior to
spirin (77). On the basis of these results, clopidogrel was
pproved by the FDA for the reduction of ischemic events
n patients with PAD. The ADA consensus recommends
hat patients with diabetes should be on an antiplatelet ogent, and that those with PAD may benefit more by taking
lopidogrel than aspirin (12).
ymptomatic PAD. To relieve the symptoms of intermit-
ent claudication, patients should exercise regularly. The
est results with exercise therapy are achieved under super-
ision, and should consist of repetitive daily walks with
ntermittent periods of rest and weekly increases in walking
ime and distance (14,78). Drug therapy can be added as
djunctive treatment to an exercise program, although this
ombination has not been well studied (55).
Currently, two medications are approved in the U.S. for
he symptomatic treatment of intermittent claudication:
entoxifylline and cilostazol. Pentoxifylline, a hemorrheo-
ogical agent, decreases blood viscosity and improves
rythrocyte flexibility (79). The results of clinical trials
emonstrating the efficacy of pentoxifylline in improving
readmill-walking distance have been equivocal, and there
re insufficient data to justify generalized use in PAD (80).
ilostazol, a phosphodiesterase inhibitor, is probably the
ost effective agent available in the U.S. Cilostazol (100 mg
wice daily) has been shown to improve maximal walking
istance by 40% to 50% compared with placebo (81,82). In
direct comparison, the mean maximal walking distance in
AD patients treated with cilostazol for 24 weeks was
ignificantly greater compared with that of patients who
eceived pentoxifylline or placebo (107, 64, and 65 m,
espectively) (Fig. 3) (83). Because of concerns about the
otential risk of mortality, cilostazol is contraindicated if any
egree of systolic or diastolic heart failure is present (12).
Various studies have evaluated prostacyclin, prostacyclin
nalogues (iloprost and beraprost), and intravenous infusion
igure 2. Relative-risk reduction and 95% confidence interval by disease
ubgroup in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic
vents (CAPRIE) trial. MI  myocardial infarction; PAD  peripheral
rterial disease. Reprinted with permission from Elsevier (Lancet 1996;
48:1329–39).f prostaglandin E1 for the treatment of intermittent clau-
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March 7, 2006:921–9 PAD in Patients With Diabetesication. The results of these studies have been inconsistent.
n a meta-analysis of five placebo-controlled trials, iloprost
emonstrated a 21% increase in ulcer healing rates in
atients with Fontaine stage 4 PAD compared with placebo
84). Furthermore, in another pooled analysis, patients with
ntermittent claudication who were randomized to receive
ral prostanoids demonstrated a 30% improvement in mean
aximum walking distance compared with subjects receiv-
ng the placebo (85). However, in a study by Mohler et al.
86) in which 897 patients with intermittent claudication
ere randomized to receive beraprost or placebo in a
ouble-blinded manner for one year, there was no signifi-
ant improvement in maximum walking distance in the
eraprost group compared with the placebo group. Admin-
stration of beraprost did not improve the pain-free walking
istance, and there was no improvement in the quality-of-
ife measures between the treatment groups. Therefore,
rostaglandins cannot be recommended for the treatment of
ither claudication or CLI.
LI. Critical limb ischemia is the precursor of limb loss and
equires urgent treatment. Conservative management in-
ludes limited debridement of ulcers, the provision of
ppropriate footwear, use of non-adherent dressings, insti-
ution of adjunctive wound-healing techniques, and treat-
ent of infection (unloading of the foot and administration
f antibiotics). Surgical drainage and debridement are often
equired to resolve the infection, and revascularization is
sually indicated (12). Indeed, revascularization is the pre-
erred treatment in patients with CLI, as surgical debride-
ent without revascularization tends to lead to larger
on-healing wounds. Successful management of CLI requires
ot only treatment of the presenting symptoms (ulceration and
nfection), but also of the underlying ischemia.
evascularization. Many patients may not experience op-
imal improvement in symptoms with medical therapy alone
82). Over recent years, revascularization has emerged as an
igure 3. The mean maximal walking distance increase from baseline in
atients with peripheral arterial disease after 24 weeks of treatment with
lacebo (n  239), pentoxifylline 400 mg three times daily (n  232), or
ilostazol 100 mg twice daily (n 227). p 0.001 vs. pentoxifylline (84).mportant strategy for management of these patients. Two Aeneral revascularization techniques exist: endovascular in-
erventions and open surgical procedures. Endovascular
evascularization has increased in popularity in recent years;
ata available from the U.S. reveals a more than five-fold
ncrease in endovascular interventions from 1980 to 2000 (87).
In general, endovascular revascularization is more appro-
riate in patients with relatively focal disease in arteries
bove the knee; however, short-term success rates for
pening long totally occluded vessels and below-the-knee
rteries are improving. To date, the best results have been
chieved in the aortoiliac vessels, where one-year patency
ates of 80% to 90% have been demonstrated (17,88).
In diabetes, open surgical revascularization tends to have
reater durability than endovascular procedures. Bypass to
he tibial or pedal vessels with autogenous vein is the most
redictable method of improving blood flow to the threat-
ned limb (12). Indeed, surgical bypass with greater saphe-
ous vein is the procedure of choice for patients with
iabetes and tibial disease.
Revascularization is the definitive therapy for the man-
gement of patients with CLI, with the aim of healing
schemic ulcers and preventing limb loss. Surgical revascu-
arization is generally superior to endovascular procedures
3). Although most ischemic limbs can be revascularized,
ack of a target vessel, unavailability of an autogenous vein,
r irreversible gangrene may mean that some cannot. In
hese patients, amputation may be a better option than
rolonged medical treatment (12).
mputation. A careful program of medical and surgical
nterventions can prevent most limb amputations. However,
mputation may represent an acceptable option for patients
acing a prolonged course of treatment and a poor prognosis
or a successful outcome. Amputation is indicated when
here is overwhelming infection that threatens the patient’s
ife, or when necrosis secondary to a major arterial occlusion
as destroyed the foot.
ONCLUSIONS
eripheral arterial disease is a common cardiovascular com-
lication in patients with diabetes. The risk of developing
AD is much higher in patients with diabetes, and the
isease is more severe and progresses more rapidly than in
on-diabetic individuals. Moreover, the presence of PAD is
potent marker of increased cardiovascular risk. If PAD is
dentified on the basis of an ABI of 0.90, its prevalence in
atients with diabetes may be as high as 29%.
Because the major threat to patients with diabetes and
AD is from cardiovascular events, the primary therapeutic
oal is to modify atherosclerotic risk factors. Risk factor
anagement includes lifestyle modifications, treating asso-
iated conditions (diabetes, dyslipidemia, and hyperten-
ion), and preventing ischemic events with aggressive
ntiplatelet therapy such as clopidogrel. Pharmacologic
herapies to improve symptomatic PAD include cilostazol.supervised exercise program or cilostazol are the preferred
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PAD in Patients With Diabetes March 7, 2006:921–9rst treatment steps for the management of symptomatic
AD. Revascularization has an important role to play in the
anagement of patients for whom risk factor modification
nd pharmacological treatment prove inadequate.
The ADA consensus statement strongly recommends
hat cardiologists act cooperatively and effectively with other
linical specialists in order to reduce the atherothrombotic
vents that too often result in much of the death and
isability in patients with diabetes and PAD.
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